BPC November 13 update

Myovant MYOV shares rally on Urovant UROV buyout; ​Kazia KZIA heads higher ahead of data next week

Price and Volume Movers

Kazia Therapeutics Limited (NASDAQ:KZIA) shares closed up 30% to $8.98. The company is due to present further data from its trial of Paxalisib (GDC-0084) in patients with Glioblastoma at the Society for Neuro-Oncology meeting on November 20, 2020. Data from its Phase 1 trial in patients in newly diagnosed diffuse intrinsic pontine glioma (DIPG) will also be presented.

Urovant Sciences (NASDAQ:UROV) shares closed up 93% to $16.02 on news released late-Thursday that Sumitovant Biopharma will acquire the outstanding shares of Urovant not already owned by Sumitovant at a price of $16.25 per share in cash.

Myovant Sciences Ltd. (NASDAQ:MYOV) made a positive move in sympathy to the Urovant news, closing up 16% to $19.83, with investors anticipating a similar result for Myovant with Sumitovant being the majority shareholder of both Urovant and Myovant.

PLx Pharma Inc. (NASDAQ: PLXP) shares closed up 17% to $4.30. The company announced that its third quarter financial results call has been rescheduled from Friday, November 16 to Monday, November 16, 2020. No reason was provided for the change.

-

Major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Navidea Biopharmaceuticals, Inc. (NAVB): $2.76; +23%.

Aerpio Pharmaceuticals, Inc. (ARPO): $1.68; +21%.

Summit Therapeutics Inc. (SMMT): $4.85; +18%.

Larimar Therapeutics, Inc. (LRMR): $22.50; +17%.

Aligos Therapeutics, Inc. (ALGS): $19.70; +16%.

DECLINERS:

Cassava Sciences, Inc. (SAVA): $8.37; -25%.

Liminal BioSciences Inc. (LMNL): $3.68; -11%.

Akers Biosciences, Inc. (AKER): $2.01; -9%.

Oramed Pharmaceuticals Inc. (ORMP): $2.54; -8%.

Adial Pharmaceuticals, Inc. (ADIL): $1.84; -8%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ATOS – Atossa Therapeutics Inc.
Endoxifen
Mammographic breast density (MBD)

Phase 2 Phase 2 initiation due in 2020 (Sweden).
$18.5 million

BBIO – BridgeBio Pharma Inc.
BBP-398
Solid tumors

Phase 1 Phase 1 initiation of dosing announced November 13, 2020.
$6.2 billion

BPTH – Bio-Path Holdings Inc.
Prexigebersen
Solid tumors

Phase 1 Phase 1 trial to commence in 4Q 2020.
$16.1 million

CFRX – ContraFect Corporation
CF-301 exebacase
Serious infections caused byStaph aureus including MRSA

Phase 3 Phase 3 initiation of dosing announced January 10, 2020. Continues to enroll as of November 2020.
$175.8 million

CMPI – Checkmate Pharmaceuticals Inc.
CMP-001 and pembrolizumab
Head and neck squamous cell carcinoma (HNSCC)

Phase 2 Phase 2 trial planned late 2020/early 2021.
$261.4 million

HRTX – Heron Therapeutics Inc.
HTX-011
Post operative pain

NDA Filing CRL announced June 29, 2020. NDA resubmission announced November 13, 2020.
$1.6 billion

MIST – Milestone Pharmaceuticals Inc.
Etripamil - RAPID
Paroxysmal supraventricular tachycardia (PSVT)

Phase 3 Phase 3 commencement of enrollment announced November 18, 2020. Data due late 2021/early 2022.
$199.8 million

MRK – Merck & Company Inc. (new)
Keytruda KN-355
Triple negative breast cancer (TNBC)

Approved FDA Approval announced November 13, 2020.
$203.4 billion

PMVP – PMV Pharmaceuticals Inc.
PC14586
Solid tumors

Phase 1/2 Phase 1/2 dosing of first patient announced November 23, 2020.
$1.6 billion

PRVL – Prevail Therapeutics Inc.
PR001 (PROPEL)
Parkinson’s disease with GBA1 mutation

Phase 1/2 Phase 1/2 biomarker and safety analysis due mid-2021.
$351.7 million

PRVL – Prevail Therapeutics Inc.
PR006 (PROCLAIM)
Frontotemporal Dementia Patients with GRN Mutations

Phase 1/2 Phase 1/2 trial to be initiated 4Q 2020. Biomarker and safety analysis due 2021.
$351.7 million

QLGN – Qualigen Therapeutics Inc.
AS1411
COVID-19

Phase 1/2 Phase 1/2 trial to commence 1H 2021.
$80.3 million

STTK – Shattuck Labs Inc.
SL-172154
Ovarian Cancer

Phase 1 Phase 1 dose escalation data due 2H 2021.
$1.5 billion

VCNX – Vaccinex Inc.
Pepinemab and Keytruda
Head and Neck Squamous Cell Carcinoma

Phase 1/2 Phase 1/2 trial to commence 1H 2021.
$47.2 million